Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Optimal rendezvous-point selection for robotic interception of moving objects.

Croft EA, Fenton RG, Benhabib B.

IEEE Trans Syst Man Cybern B Cybern. 1998;28(2):192-204. doi: 10.1109/3477.662759.

PMID:
18255936
2.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

3.

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Fitch TR, Fenton RG, Fonseca R, Isham CR, Ziesmer SC, Erlichman C, Bible KC.

Haematologica. 2006 Mar;91(3):390-3. Epub 2006 Feb 17.

4.

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG.

J Clin Oncol. 2005 Jun 20;23(18):4089-99. Epub 2005 May 2.

PMID:
15867202
5.

Partitioning apoptosis: a novel form of the execution phase of apoptosis.

Zhang B, Arany Z, Mann D, Rhee JG, Fenton RG.

Apoptosis. 2005 Jan;10(1):219-31.

PMID:
15711938
6.

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.

Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G.

Clin Cancer Res. 2004 Dec 15;10(24):8301-8.

7.

Bcl-2 family proteins regulate mitochondrial reactive oxygen production and protect against oxidative stress.

Kowaltowski AJ, Fenton RG, Fiskum G.

Free Radic Biol Med. 2004 Dec 1;37(11):1845-53.

PMID:
15528043
8.

Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.

Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N.

Bone Marrow Transplant. 2004 Apr;33(8):781-7.

PMID:
14767498
9.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
10.

IL-6-independent expression of Mcl-1 in human multiple myeloma.

Zhang B, Potyagaylo V, Fenton RG.

Oncogene. 2003 Mar 27;22(12):1848-59.

PMID:
12660820
13.

Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

Zhang B, Gojo I, Fenton RG.

Blood. 2002 Mar 15;99(6):1885-93.

PMID:
11877256
14.

Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.

Zhang B, Prendergast GC, Fenton RG.

Cancer Res. 2002 Jan 15;62(2):450-8.

15.

Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).

Park JW, Gruys ME, McCormick K, Lee JK, Subleski J, Wigginton JM, Fenton RG, Wang JM, Wiltrout RH.

J Immunol. 2001 Mar 15;166(6):3763-70.

16.

Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.

Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE, Roessler PG, Wiltrout RH.

J Immunol. 1999 Aug 15;163(4):1943-50.

17.

Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.

Siders WM, Halloran PJ, Fenton RG.

Cancer Gene Ther. 1998 Sep-Oct;5(5):281-91.

PMID:
9824047
18.

Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.

Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH.

J Immunol. 1998 Oct 15;161(8):3957-65.

19.
20.

Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras.

Fenton RG, Hixon JA, Wright PW, Brooks AD, Sayers TJ.

Cancer Res. 1998 Aug 1;58(15):3391-400.

21.

T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.

Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, Fenton RG.

J Immunol. 1998 Jun 1;160(11):5465-74.

22.
23.

Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus.

Vortmeyer AO, Kingma DW, Fenton RG, Curti BD, Jaffe ES, Duray PH.

Am J Clin Pathol. 1998 Jan;109(1):90-5.

PMID:
9426523
24.

Sequence analysis of a 1296-nucleotide plasmid from Xylella fastidiosa.

Pooler MR, Hartung JS, Fenton RG.

FEMS Microbiol Lett. 1997 Oct 15;155(2):217-22.

25.

Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin.

Taub DD, Murphy WJ, Asai O, Fenton RG, Peltz G, Key ML, Turcovski-Corrales S, Longo DL.

J Immunol. 1997 Mar 15;158(6):2745-55.

PMID:
9058809
26.

Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes.

Fenton RG, Longo DL.

J Natl Cancer Inst. 1997 Feb 19;89(4):272-5. Review. No abstract available.

PMID:
9048827
27.

Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.

Siders WM, Halloran PJ, Fenton RG.

Cancer Res. 1996 Dec 15;56(24):5638-46.

28.

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74.

PMID:
8941876
29.

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.

J Clin Oncol. 1996 Aug;14(8):2234-41.

PMID:
8708712
30.

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.

Curti BD, Ochoa AC, Urba WJ, Alvord WG, Kopp WC, Powers G, Hawk C, Creekmore SP, Gause BL, Janik JE, Holmlund JT, Kremers P, Fenton RG, Miller L, Sznol M, Smith JW 2nd, Sharfman WH, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):296-308.

PMID:
8877723
31.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd.

J Natl Cancer Inst. 1996 Jan 3;88(1):44-9.

PMID:
8847725
32.
33.

Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.

Fenton RG, Keller CJ, Hanna N, Taub DD.

J Natl Cancer Inst. 1995 Dec 20;87(24):1853-61.

PMID:
7494229
34.

CD28:B7 interactions promote T cell adhesion.

Turcovski-Corrales SM, Fenton RG, Peltz G, Taub DD.

Eur J Immunol. 1995 Nov;25(11):3087-93.

PMID:
7489747
35.

Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma.

Esteva-Lorenzo FJ, Janik JE, Fenton RG, Emslie-Smith A, Engel AG, Longo DL.

Cancer. 1995 Oct 1;76(7):1219-23.

PMID:
8630901
36.

CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.

Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA.

Cancer Res. 1995 Jul 15;55(14):2984-7.

37.

Genetic instability and tumor cell variation: implications for immunotherapy.

Fenton RG, Longo DL.

J Natl Cancer Inst. 1995 Feb 15;87(4):241-3. No abstract available.

PMID:
7707413
38.

Cellular and molecular studies in the treatment of murine renal cancer.

Wiltrout RH, Gregorio TA, Fenton RG, Longo DL, Ghosh P, Murphy WJ, Komschlies KL.

Semin Oncol. 1995 Feb;22(1):9-16. Review.

PMID:
7855624
39.

A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.

Holmund JT, Kopp WC, Wiltrout RH, Longo DL, Urba WJ, Janik JE, Sznol M, Conlon KC, Fenton RG, Hornung R, et al.

J Natl Cancer Inst. 1995 Jan 18;87(2):134-6. No abstract available.

PMID:
7707385
40.

Cloning and analysis of MAGE-1-related genes.

Ding M, Beck RJ, Keller CJ, Fenton RG.

Biochem Biophys Res Commun. 1994 Jul 15;202(1):549-55.

PMID:
8037761
41.

Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.

Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL.

J Natl Cancer Inst. 1993 Aug 18;85(16):1294-302.

PMID:
8340941
42.

Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.

Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW 2nd, Alvord WG, Creekmore SP, Fenton RG, Gause BL, Holmlund J, et al.

J Clin Oncol. 1993 Apr;11(4):652-60.

PMID:
8257476
43.

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.

Smith JW 2nd, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG, et al.

N Engl J Med. 1993 Mar 18;328(11):756-61.

44.

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al.

J Clin Oncol. 1993 Jan;11(1):125-35.

PMID:
8418223
45.

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al.

J Clin Oncol. 1992 Jul;10(7):1141-52.

PMID:
1607919
46.

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL.

Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs].

PMID:
1343617
47.

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al.

J Natl Cancer Inst. 1992 Jun 17;84(12):929-37.

PMID:
1629914
48.

Regulation of intracellular actin polymerization by prenylated cellular proteins.

Fenton RG, Kung HF, Longo DL, Smith MR.

J Cell Biol. 1992 Apr;117(2):347-56.

49.

Isotypic exclusion of gamma delta T cell receptors in transgenic mice bearing a rearranged beta-chain gene.

Fenton RG, Marrack P, Kappler JW, Kanagawa O, Seidman JG.

Science. 1988 Aug 26;241(4869):1089-92.

PMID:
2970670
50.

Changes in the topography of early region transcription during polyoma virus lytic infection.

Fenton RG, Basilico C.

Proc Natl Acad Sci U S A. 1982 Dec;79(23):7142-6.

Supplemental Content

Loading ...
Support Center